Efficacy and safety of ecabet sodium on functional dyspepsia: A prospective, double-blinded, randomized, multi-center controlled trial

Table 1 Demographic characteristics of the enrolled patients

Group	Ecabet group	Cimetidine group	P
	(n = 133)	(n = 139)
Gender (male:female)	47:86	47:92	NS
Age (yr)	45.0 ± 12.9	47.5 ± 12.5	NS
Weight (kg)	59.6 ± 10.0	58.5 ± 9.0	NS
Height (cm)	162.7 ± 8.0	161.8 ± 7.7	NS
Smoking (%)	23 (17.3)	16 (11.5)	NS
Alcohol intake (%)	47 (35.3)	38 (27.3)	NS

Table 2 Prevalence of Helicobacter pylori infection

Group	Positive (%)	Negative (%)	Undetermined (%)
Ecabet group	44	45	31
(n = 120)	(36.7)	(37.5)	(25.9)
Cimetidine group	40	60	28
(n = 128)	(31.3)	(46.9)	(21.9)

Pearson's chi-square test; P = NS.

Table 3 Global assessment of symptomatic improvement after 4 wk of medication

Group	Ecabet group	Cimetidine group
	(n = 115) (%)	(n = 121) (%)
Improved	89 (77.4)	96 (79.3)
Not improved	26 (22.6)	25 (20.7)

Pearson's chi-square test: P = 0.71.

Table 4 Comparison of quality of life scores before and after treatment (mean±SD)

Status	Before treatment			After treatment
	Ecabet group(n = 115)	Cimetidine group(n = 121)	P	Ecabet group(n = 115)	Cimetidine group(n = 121)	P
Eating status	15.0 ± 4.6	14.8 ± 4.1	NS	15.6 ± 4.0	15.9 ± 3.5	NS
Liveliness status	10.4 ± 4.1	10.0 ± 4.0	NS	11.6 ± 3.6	11.3 ± 3.5	NS
Psychological status	18.5 ± 5.0	18.6 ± 4.5	NS	20.3 ± 4.4	20.4 ± 4.1	NS
Role-functioning status	20.5 ± 4.2	20.6 ± 4.2	NS	21.4 ± 3.9	21.0 ± 4.3	NS

Table 5 Comparison of global symptomatic improvement by H pylori status

H pylori infection	Gastrex group		Cimetidine group
	Improved (%)	Not improved(%)	Improved (%)	Not improved (%)
Negative	28 (84.85)	5 (15.15)	27 (84.38)	5 (15.63)
Positive	28 (75.68)	9 (24.32)	24 (72.73)	9 (27.27)

Chi square test, P = 0.89.

Table 6 Comparison of global symptomatic improvement by age

Age	Gastrex group		Cimetidine group
	Improveed (%)	Not improved (%)	Improved (%)	Not improved (%)
Less than fifty	55 (61.8)	14 (53.85)	61 (63.54)	12 (48.0)
fifty and over	34 (38.2)	12 (46.15)	35 (36.46)	13 (52.0)

Chi square test, P = 0.63.

Table 7 Comparison of global symptomatic improvement by sex

Sex	Gastrex group		Cimetidine group
	Improved (%)	Not improved (%)	Improved (%)	Not improved (%)
Men	27 (71.05)	11 (28.94)	34 (79.07)	9 (20.93)
Women	63 (80.76)	15 (19.23)	62 (79.48)	16 (20.51)

Chi square test, P = 0.79.